Clinical trials
Tislelizumab clinical trials
Below are recruiting tislelizumab clinical trials, each written for real people, not researchers. We’re tracking 218 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT07099547RecruitingPhase 2
ZG005 plus chemo for advanced gallbladder cancer
This trial tests a new drug called ZG005 combined with standard chemotherapy for people with advanced gallbladder cancer. The goal is to see if adding ZG005 helps shrink tumors or slow the disease.
Hefei, AnhuiAges 18–75 - NCT07331155RecruitingPhase 2
LBL-024 combo for advanced esophageal cancer
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07109401RecruitingPhase 2
Immunotherapy for early-stage small cell lung cancer that can be removed with surgery
This trial tests whether giving immunotherapy before and after surgery can help people with limited-stage small cell lung cancer. It is for patients whose cancer has not spread widely and can be completely removed by surgery.
ShanghaiAges 18–75 - NCT05978102RecruitingPhase 1/Phase 2
Study of STI-7349 for advanced solid cancers
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
Yiwu, ZhejiangAges 18–80 - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT06030258RecruitingPhase 1/Phase 2
Study of IN10018 plus standard chemo for extensive-stage small cell lung cancer
This trial tests a new drug called IN10018 combined with standard chemotherapy (carboplatin and etoposide) and an immunotherapy (anti-PD-1/L1) for people with extensive-stage small cell lung cancer (ES-SCLC) who have not yet been treated. The goal is to see if adding IN10018 helps shrink tumors or slow the cancer's growth.
JinanAges 18–75 - NCT06463444RecruitingPhase 1
Precision treatment for inoperable liver cancer
This trial tests a new precision approach for people with liver cancer that cannot be removed by surgery. It uses a computer model to analyze your tumor and genetic information to see if combining HAIC (chemotherapy directly into the liver), lenvatinib (a targeted drug), and a PD-1 inhibitor (immunotherapy) is the right treatment for you.
Wuhan, HubeiAges 18–75 - NCT07390383RecruitingPhase 2
LBL-024 combo for advanced gastric cancer
This trial tests a new combination drug called LBL-024 in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the treatment can help shrink the tumor or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07413042RecruitingPhase 1
Radiation drug combined with immunotherapy for extensive-stage small cell lung cancer
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
Beijing, Beijing MunicipalityAges 18–80 - NCT06233942RecruitingPhase 1
Testing a new drug for advanced solid tumors
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT04837859RecruitingPhase 2
Personalized immunotherapy for early-stage unfavorable Hodgkin lymphoma
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
CologneAges 18 years+ - NCT06764355RecruitingPhase 2
Chemo, Immunotherapy, and Chemoradiation Before Surgery for Advanced Esophageal Cancer
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
TaipeiAges 18–75 - NCT06868732RecruitingPhase 1
A new drug combination for advanced non-small cell lung cancer
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06966154RecruitingPhase 1/Phase 2
Tislelizumab with golidocitinib and selinexor for NK/T-cell lymphoma
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
Shanghai, ShangaiAges 18 years+ - NCT06881537RecruitingPhase 2
Chemo and targeted therapy before surgery for recurrent colorectal cancer
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
ShanghaiAges 18–75 - NCT06312982RecruitingPhase 2/Phase 3
Chemo, radiation, and immunotherapy before rectal cancer surgery
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06596473RecruitingPhase 1
Study of BG-C477 for advanced solid tumors
This trial tests a new drug called BG-C477 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
Goodyear, ArizonaAges 18 years+ - NCT06132698RecruitingPhase 2
Immunotherapy injected into spinal fluid for lung cancer that has spread to the brain lining
This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.
Chengdu, SichuanAges 18–75 - NCT07290985RecruitingPhase 2
Can biomarkers guide organ-sparing treatment for stomach and esophagus cancer?
This trial tests if using specific biomarkers (like HER2 and PD-L1) can help choose the best treatment to potentially avoid surgery. It aims to preserve the stomach or esophagus while effectively treating the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07744698RecruitingPhase 4
Maintenance therapy for advanced lung cancer
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hefei, AnhuiAges 18–75 - NCT04501523RecruitingPhase 2
ctDNA-guided immunotherapy boost after chemotherapy for triple-negative breast cancer
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Guandong, GuangdongAges 18–80 - NCT04973306RecruitingPhase 2/Phase 3
Chemo-immunotherapy before surgery versus chemo-radiation
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
ShanghaiAges 18–75
Hear when a new Tislelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tislelizumab?
- Yes. Clin2 currently lists 218 recruiting tislelizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tislelizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tislelizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.